mirtazapine has been researched along with Obesity in 4 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mirtazapine, a widely used antidepressant, induces adverse metabolic effects such as an increase in body weight." | 5.12 | Effect of mirtazapine treatment on body composition and metabolism. ( Deisenhammer, EA; Ebenbichler, CF; Engl, J; Hinterhuber, H; Kramer-Reinstadler, K; Laimer, M; Lechner-Schoner, T; Patsch, JR; Rauchenzauner, M; Strauss, R, 2006) |
| "Fluoxetine was the reference treatment option in the medication models." | 1.39 | Influence of body mass index on the choice of therapy for depression and follow-up care. ( Arterburn, D; Bogart, A; Boudreau, DM; Haneuse, S; Simon, G; Theis, MK; Westbrook, E, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Puzhko, S | 1 |
| Schuster, T | 1 |
| Barnett, TA | 1 |
| Renoux, C | 1 |
| Munro, K | 1 |
| Barber, D | 1 |
| Bartlett, G | 1 |
| Boudreau, DM | 1 |
| Arterburn, D | 1 |
| Bogart, A | 1 |
| Haneuse, S | 1 |
| Theis, MK | 1 |
| Westbrook, E | 1 |
| Simon, G | 1 |
| Fisfalen, ME | 1 |
| Hsiung, RC | 1 |
| Laimer, M | 1 |
| Kramer-Reinstadler, K | 1 |
| Rauchenzauner, M | 1 |
| Lechner-Schoner, T | 1 |
| Strauss, R | 1 |
| Engl, J | 1 |
| Deisenhammer, EA | 1 |
| Hinterhuber, H | 1 |
| Patsch, JR | 1 |
| Ebenbichler, CF | 1 |
1 trial available for mirtazapine and Obesity
| Article | Year |
|---|---|
Effect of mirtazapine treatment on body composition and metabolism.
Topics: Adipose Tissue; Adult; Antidepressive Agents, Tricyclic; Blood Glucose; Body Composition; Body Fat D | 2006 |
3 other studies available for mirtazapine and Obesity
| Article | Year |
|---|---|
Difference in patterns of prescribing antidepressants known for their weight-modulating and cardiovascular side effects for patients with obesity compared to patients with normal weight.
Topics: Adult; Antidepressive Agents; Canada; Citalopram; Female; Humans; Mirtazapine; Obesity | 2021 |
Influence of body mass index on the choice of therapy for depression and follow-up care.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Choice Behavior; Cohort Studies; De | 2013 |
Glucose dysregulation and mirtazapine-induced weight gain.
Topics: Adult; Antidepressive Agents, Tricyclic; Blood Glucose; Body Mass Index; Cocaine-Related Disorders; | 2003 |